Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Tapeworm Treatment Shows Early Effectiveness Against Endometriosis : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-10-03

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of five claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

  • 2 supported
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredTwo weeks after a single injection, mice receiving the drug had fewer and smaller lesions than controls, and some mice had no detectable lesions at that assessment.View evidenceHide evidence

As stated4 of 8 mice in the lower-dose group and 5 of 8 in the higher-dose group had no detectable lesions

Why this verdict

The abstract-level profile supports the general finding that a single dose at 25 or 50 mg/kg significantly suppressed lesion number and volume at 2 weeks. However, it does not provide the specific sample sizes or the stated counts/proportions of mice with no detectable lesions, nor detailed control-group numbers. Those precise magnitude claims are not verifiable from the abstract profile.

1

Study evidence

A single intraperitoneal dose of FA-2DG-D-Niclo (25 or 50 mg/kg niclosamide-equivalent) significantly reduced FRβ+ macrophage burden at 2 weeks post-treatment in a mouse endometriosis model.

“A single intraperitoneal dose of FA-2DG-D-Niclo (25 or 50 mg/kg/bw of niclosamide) significantly reduced FRβ+ macrophage burden, suppressed lesion number and volume, and markedly improved EuE-associated hyperalgesia at 2 weeks post-treatment.”
Claim 2 of 5Not coveredBoth doses eased heightened pain-related sensitivity in the mice, as measured by withdrawal responses to pressure on the abdomen and hind paws.View evidenceHide evidence

Why this verdict

The profile supports that both 25 and 50 mg/kg niclosamide-equivalent dosing markedly improved endometriosis-associated hyperalgesia at 2 weeks. But the abstract profile does not specify the behavioral assay details, including withdrawal responses to abdominal and hind-paw pressure, so the measurement-specific part of the claim is not verifiable at this evidence depth.

1

Study evidence

A single intraperitoneal dose of FA-2DG-D-Niclo (25 or 50 mg/kg niclosamide-equivalent) significantly reduced FRβ+ macrophage burden at 2 weeks post-treatment in a mouse endometriosis model.

“A single intraperitoneal dose of FA-2DG-D-Niclo (25 or 50 mg/kg/bw of niclosamide) significantly reduced FRβ+ macrophage burden, suppressed lesion number and volume, and markedly improved EuE-associated hyperalgesia at 2 weeks post-treatment.”
Claim 3 of 5Not coveredThe article says the study is still preclinical, with small treatment groups, only two weeks of follow-up, and no established long-term benefit, repeated-dose safety, or human effectiveness.View evidenceHide evidence

Why this verdict

The main caveats are directionally consistent with the profile: this is a preclinical mouse study, assessed at a 2-week post-treatment timepoint, with no human effectiveness evidence and no long-term efficacy established. However, the abstract profile does not verify the asserted small treatment groups, and repeated-dose safety is not specifically characterized there beyond the fact that efficacy was tested after a single dose. Thus the full caveat package is only partly verifiable at abstract depth.

1

Study evidence

A single intraperitoneal dose of FA-2DG-D-Niclo (25 or 50 mg/kg niclosamide-equivalent) significantly reduced FRβ+ macrophage burden at 2 weeks post-treatment in a mouse endometriosis model.

“A single intraperitoneal dose of FA-2DG-D-Niclo (25 or 50 mg/kg/bw of niclosamide) significantly reduced FRβ+ macrophage burden, suppressed lesion number and volume, and markedly improved EuE-associated hyperalgesia at 2 weeks post-treatment.”
Claim 4 of 5SupportedA new study published in Advanced Healthcare Materials found that a version of niclosamide attached to a specially designed carrier reduced endometriosis-associated growths and pain-related sensitivity in mice.View evidenceHide evidence

As statedreduced endometriosis-associated growths and pain-related sensitivity

Why this verdict

The abstract-level profile supports that FA-2DG-D-Niclo, a dendrimer-conjugated niclosamide nanotherapeutic, was tested in mice and significantly reduced lesion number/volume and improved endometriosis-associated hyperalgesia at 2 weeks. The story frames this as an in-mice preclinical finding rather than human efficacy, so the causal wording is supported for the animal intervention experiment.

1

Study evidence

A single intraperitoneal dose of FA-2DG-D-Niclo (25 or 50 mg/kg niclosamide-equivalent) significantly reduced FRβ+ macrophage burden at 2 weeks post-treatment in a mouse endometriosis model.

“A single intraperitoneal dose of FA-2DG-D-Niclo (25 or 50 mg/kg/bw of niclosamide) significantly reduced FRβ+ macrophage burden, suppressed lesion number and volume, and markedly improved EuE-associated hyperalgesia at 2 weeks post-treatment.”
2

Study evidence

FA-2DG-D was synthesized via click chemistry and functionalized with folic acid to enable FRβ-targeting.

“we engineered a folic acid (FA)-conjugated 2-deoxyglucose dendrimer (FA-2DG-D) using click chemistry”
Claim 5 of 5SupportedThe researchers designed a dendrimer carrier with folic acid to target FRβ-positive macrophages and improve niclosamide delivery and water solubility.View evidenceHide evidence

Why this verdict

The profile states that the researchers engineered a folic acid–conjugated 2-deoxyglucose dendrimer, conjugated niclosamide to it, reported enhanced aqueous solubility and controlled intracellular release, and showed lesion accumulation/selective internalization by FRβ+ macrophages in mice. The story’s carrier-design and targeting/solubility claim is therefore supported at abstract depth.

1

Study evidence

FA-2DG-D was synthesized via click chemistry and functionalized with folic acid to enable FRβ-targeting.

“we engineered a folic acid (FA)-conjugated 2-deoxyglucose dendrimer (FA-2DG-D) using click chemistry”
2

Study evidence

FA-2DG-D demonstrated lesion-specific accumulation in a mouse model of endometriosis.

“In a mouse model of EuE, FA-2DG-D demonstrated lesion-specific accumulation and selective internalization by FRβ+ macrophages with minimal off-target organ retention.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • In vivo targeting/biodistribution evidence: FA-2DG-D showed lesion-specific accumulation, selective internalization by FRβ+ macrophages, and minimal off-target organ retention in the mouse model.

    The story mentions the carrier as targeting FRβ-positive macrophages, but it does not clearly report the paper’s separate biodistribution/uptake evidence or the minimal off-target organ-retention claim. Design intent is reflected, but the demonstrated targeting/biodistribution result is not fully conveyed.

    From in_vivo_animal biodistribution/targeting

  • Reduction in FRβ+ macrophage burden as an efficacy endpoint and part of the macrophage-targeted therapeutic rationale.

    The profile identifies reduced FRβ+ macrophage burden as one of the reported treatment effects, and also frames FRβ+ macrophages as contributors to disease progression. The story mentions targeting FRβ-positive macrophages but does not state that treatment reduced FRβ+ macrophage burden.

    From in vivo mouse endometriosis efficacy study; other

  • Mechanistic/biological premise that FRβ+ macrophages contribute to endometriosis progression and that niclosamide affects inflammation, innervation, and angiogenesis.

    The story captures the targeting concept but does not discuss the broader mechanistic claims around inflammation, innervation, angiogenesis, or the abstract’s statement that FRβ+ macrophages contribute to disease progression. At abstract depth, this mechanistic unit is itself somewhat ambiguous as to what is new versus background.

    From other

3 things the story did carry across
  • Development of FA-2DG-D-Niclo: a folic acid–conjugated 2-deoxyglucose dendrimer carrying niclosamide, with reported enhanced aqueous solubility and controlled intracellular release.
  • Therapeutic efficacy in a mouse endometriosis model after a single intraperitoneal dose, with reduced lesion number/volume and improved hyperalgesia at 2 weeks.
  • Key translational limitations: mouse model only, preclinical status, short 2-week follow-up, and no demonstrated human effectiveness or long-term benefit.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalTest therapeutic efficacy of FA-2DG-D-Niclo in a mouse endometriosis model (reduction in FRβ+ macrophage burden, lesion number/volume, and hyperalgesia after a single intraperitoneal dose).in vivo mouse endometriosis efficacy studyExpand

In plain English

In a mouse model of endometriosis, a folic-acid–conjugated 2-deoxyglucose dendrimer carrying niclosamide (FA-2DG-D-Niclo) administered as a single intraperitoneal dose (25 or 50 mg/kg niclosamide-equivalent) showed lesion-specific accumulation and selective internalization by FRβ+ macrophages and, at 2 weeks post-treatment, significantly reduced FRβ+ macrophage burden, decreased lesion number and volume, and markedly improved endometriosis-associated hyperalgesia.

Key findings

  • A single intraperitoneal dose of FA-2DG-D-Niclo (25 or 50 mg/kg niclosamide-equivalent) significantly reduced FRβ+ macrophage burden at 2 weeks post-treatment in a mouse endometriosis model.
  • A single intraperitoneal dose of FA-2DG-D-Niclo (25 or 50 mg/kg niclosamide-equivalent) significantly suppressed lesion number and lesion volume at 2 weeks post-treatment.
“A single intraperitoneal dose of FA-2DG-D-Niclo (25 or 50 mg/kg/bw of niclosamide) significantly reduced FRβ+ macrophage burden, suppressed lesion number and volume, and markedly improved EuE-associated hyperalgesia at 2 weeks post-treatment.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2in vitroDevelop and characterize a folic acid–conjugated 2-deoxyglucose dendrimer nanocarrier for targeted niclosamide delivery (FA-2DG-D-Niclo) with improved solubility, controlled intracellular release, and reproducible manufacture.chemical synthesis and bench characterizationExpand

In plain English

The authors report engineering a folic acid–conjugated 2-deoxyglucose dendrimer (FA-2DG-D) via click chemistry and conjugating the anthelmintic drug niclosamide to produce a targeted nanotherapeutic (FA-2DG-D-Niclo). In the abstract they claim the conjugate has enhanced aqueous solubility, controlled intracellular release, and excellent batch-to-batch reproducibility and was designed to enable selective FRβ-mediated uptake.

Key findings

  • FA-2DG-D was synthesized via click chemistry and functionalized with folic acid to enable FRβ-targeting.
  • Conjugation of niclosamide to FA-2DG-D produced FA-2DG-D-Niclo with enhanced aqueous solubility relative to free drug (as reported).
“we engineered a folic acid (FA)-conjugated 2-deoxyglucose dendrimer (FA-2DG-D) using click chemistry”
What this piece can’t prove

3 further details could not be confirmed from the summary.

3in vivo animalDemonstrate lesion-targeted accumulation and selective uptake of the FA-2DG-D platform by FRβ-expressing macrophages in a mouse model of endometriosis, with minimal off-target organ retention.in vivo animal biodistribution/targetingExpand

In plain English

In a mouse model of endometriosis, the FA-2DG-D dendrimer platform showed lesion-specific accumulation and was reported to be selectively internalized by FRβ-expressing macrophages, with minimal retention in non-target organs, based on the study abstract.

Key findings

  • FA-2DG-D demonstrated lesion-specific accumulation in a mouse model of endometriosis.
  • FA-2DG-D was selectively internalized by FRβ-expressing macrophages in lesions.
“In a mouse model of EuE, FA-2DG-D demonstrated lesion-specific accumulation and selective internalization by FRβ+ macrophages with minimal off-target organ retention.”
What this piece can’t prove
  • The abstract does not report sample sizes, time points, imaging/modalities, or detailed organ distribution data.

3 further details could not be confirmed from the summary.

4otherSupport the mechanistic/biological premise that FRβ+ macrophages are key contributors/targets in endometriosis progression and inflammation/innervation/angiogenesis, motivating the targeted approach.Expand

In plain English

The abstract reports that folate receptor-β (FRβ)-positive macrophages were identified as contributors to endometriosis progression and that niclosamide inhibits FRβ+ macrophages, with associated reductions in inflammation, innervation, and angiogenesis. These statements are presented as the mechanistic/target rationale motivating a macrophage-targeted niclosamide nanotherapy.

Key findings

  • The abstract reports that FRβ+ macrophages are contributors to endometriosis progression and that niclosamide inhibits FRβ+ macrophages, reducing inflammation, innervation, and angiogenesis.
“We further identified folate receptor-β (FRβ)-positive macrophages as contributors to disease progression.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Specific targeting of folate–dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts

Magnetic Resonance Materials in Biology, Physics, and Medicine · 2001 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.